Results 131 to 140 of about 5,501,792 (312)

Leveraging whole-genome sequencing for microbial contamination tracking and risk assessment in pharmaceutical manufacturing

Frontiers in Microbiology
BackgroundPharmaceutical cleanrooms remain vulnerable to microbial contamination introduced through environmental and personnel-associated pathways, yet the genomic characteristics and transmission dynamics of these contaminants are not well defined ...
Qiongqiong Li, Deyin Deng, Xin Dou, Xinqin Chen, Xuhua Duan, Tingzhang Wang, Minghui Song   +6 more
doaj   +1 more source

Drug Testing

Chen RJ, Cogburn M.
europepmc   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Photostability stress testing

, 2011
The problem of photostability of drugs has received relatively little attention in the pharmaceutical industry. In 1998, the implementation of the ICH guidelines as to how carry out photostability tests on new pharmaceutical drug substances and drug ...
FASANI, ELISA, ALBINI, ANGELO
core  

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Construction apprentices' attitudes to workplace drug testing in Ireland.

, 2006
Ireland has become one of the first European countries to legislate for workplace drug testing. However, little is known about the attitudes of Irish workers towards various aspects of workplace drug testing programmes.
Hogan, Victoria, Cannon, Roseanne, Nic Gabhainn, Saoirse   +2 more
core  

Interim Hearing on Drug Testing in the Workplace - Volume II [PDF]

, 1986
Five interim hearings were held in the following locations: Orange County - October 7th; San Francisco - October 14th; Los Angeles - October 16th; Sacramento - October 27th; and San Diego - October 28th.
Select Committee on Drug and Alcohol Abuse
core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

journal.ie Poll: Would you support the idea of drug testing stations at nightclubs?

, 2017
The proposal is being examined by as part of the government’s latest national drug strategy.
Brophy, Daragh
core